1. Denton CP, Abraham DJ. Transgenic analysis of scleroderma: understanding key pathogenic events in vivo [Review]. Autoimmun Rev2004;3:285–93.
2. Reveille JD. Genetic studies in the rheumatic diseases: present status and implications for the future. J Rheumatol Suppl2005;72:10–13.
3. Markiewicz M, Smith EA, Rubinchik S, Dong JY, Trojanowska M, LeRoy EC. The 72-kilodalton IE-1 protein of human cytomegalovirus (HCMV) is a potent inducer of connective tissue growth factor (CTGF) in human dermal fibroblasts. Clin Exp Rheumatol2004;22(3 Suppl. 33):S31–4.
4. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol1988;15:202–5.
5. American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum1980;23:581–90.